Press Releases

 
Press Releases
  Date Title and Summary View
Sep 21, 2016
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September 28th, ...
Sep 15, 2016
PLOS ONE publication supports phase 1/2 intrahepatic cholangiocarcinoma trial with ARQ 087 in patients with FGFR2 genetic alterations BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced the publication of a paper detailing the preclinical profile of ARQ ...
Aug 3, 2016
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2016. For the quarter ended June 30, 2016, the Company reported a net loss of ...
Jul 20, 2016
BURLINGTON, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the second quarter 2016 before the market opens on Wednesday, August 3, 2016.  The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general busin...
Jul 18, 2016
Data supports further preclinical and clinical research in BTK sensitive and ibrutinib resistant malignancies BURLINGTON, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the first public presentation of data on its novel BTK inhibitor, ARQ 531, at the 2016 Pan Pacific Lymphoma Conference in Koloa, Hawaii. ...
Jul 5, 2016
BURLINGTON, Mass., July 05, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on July 12th, 2016, at 2:30 p.m. ET at Le Parker Meridie...
Jun 30, 2016
75% disease control rate, including a 25% objective response rate, was observed in 12 evaluable patients harboring FGFR2 genetic alterations BURLINGTON, Mass., June 30, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that preliminary data presented at ESMO GI demonstrate evidence of anticancer activity, defined by objecti...
Jun 23, 2016
BURLINGTON, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that preliminary data from the ongoing phase 2 portion of a phase 1/2 trial in intrahepatic cholangiocarcinoma (iCCA) with our proprietary fibroblast growth factor receptor (FGFR) inhibitor, ARQ 087, will be presented on June 30, 2016 at the ESMO 18th ...
May 4, 2016
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced its financial results for the first quarter of 2016.  For the quarter ended March 31, 2016, the Company reported a net loss of $4,981,000 or $0.08 per share, compared with a net loss of $4,551,000 or...
Apr 20, 2016
BURLINGTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the first quarter 2016 before the market opens on Wednesday, May 4, 2016.  The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300